Project description
New clinical trial design for tuberculosis drugs
As with many bacterial diseases, tuberculosis has been hit by drug resistance, threatening the efficacy of existing treatments. Although there are new drugs for clinical evaluation, testing the different combinations is time-consuming and requires a concerted effort. The EU-funded UNITE4TB project brings together experts in the field to design and set new standards for tuberculosis Phase II clinical trials. The team will take advantage of existing networks across continents to recruit patients in trials and introduce state-of-the-art microbiology methods and machine learning technologies. Data on biomarkers and clinical pharmacology will accompany the validation of the new drugs to ensure their subsequent success down the drug discovery pipeline.
Objective
Current anti-tuberculosis (TB) drug regimens face serious limitations at times of increasing antimicrobial drug resistance. Fortunately, for the first time for centuries, several novel anti-TB compounds are available for clinical evaluation. As the traditional approach to testing these in multiple combination regimens is too slow and inefficient new approaches of clinical phase 2 study designs are required if we are to meet the targets of the WHO EndTB strategy to save the lives of millions into the near future. Our consortium brings together a unique group of European and international leaders in TB research and leading industry partners. Together we will provide the necessary comprehensive range of expertise to meet the demands of the UNITE4TB scientific research agenda. Specifically, we will develop a new global standard for phase 2 TB clinical trial designs, utilising simulation tools to identify optimal doses in phase 2A trials and apply a multi-arm multi-stage adaptive randomised controlled 2B/C trial design capable of rapid and simultaneous evaluation of the best candidate regimens. Our innovative phase 2 trials will be performed to the highest regulatory standards, incorporating state-of-the-art microbiology, biomarker investigation and clinical pharmacology. We will take advantage of existing global TB clinical trial networks with the capacity to enrol patients at an unprecedented pace and number across four continents. Artificial intelligence/machine learning technologies will be applied to validate state-of-the art molecular and imaging tools as treatment decision biomarkers with the aim of establishing new, real-time outcome measures. Our consortium will evaluate 3-5 new chemical entities (NCEs) at phase 2A and up to 17 novel combination regimens in phase 2B/C. Our objective is to identify those that have the greatest chance of success in subsequent definitive phase 3 clinical trials and of becoming the global gold-standard TB regimens of the future.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistance
- medical and health sciencesclinical medicinepneumologytuberculosis
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
- natural sciencesbiological sciencesmicrobiology
- natural sciencescomputer and information sciencessoftwaresoftware applicationssimulation software
Keywords
Programme(s)
Topic(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
6525 GA Nijmegen
Netherlands
See on map
Participants (33)
WC1E 7HT London
See on map
OX1 2JD Oxford
See on map
23845 Borstel
See on map
3521 AL Utrecht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
LA1 4YW Lancaster
See on map
WC1E 6BT London
See on map
7530 Cape Town
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
6825 ARNHEM
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
20132 Milano
See on map
85764 Neuherberg
See on map
2516 AB 's-Gravenhage (Den Haag)
See on map
2 Dublin
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
S10 2PX Sheffield
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
1040 Bruxelles / Brussel
See on map
4050 290 Porto
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
L69 7ZX Liverpool
See on map
13572 Marseille
See on map
20148 Hamburg
See on map
94607 OAKLAND CA
See on map
10005 NEW YORK
See on map
1202 Geneve
See on map
20122 Milano
See on map
KY16 9AJ St Andrews
See on map
751 05 Uppsala
See on map
1003 Lausanne
See on map
23843 Bad Oldesloe
See on map
28760 TRES CANTOS MADRID
See on map
2340 Beerse
See on map
80636 Munchen
See on map
38124 Braunschweig
See on map
80539 Muenchen
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
81377 Munchen
See on map
CB2 1TN Cambridge
See on map